Price T Rowe Associates Inc Aquestive Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 45,086 shares of AQST stock, worth $243,013. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,086
Previous 42,942
4.99%
Holding current value
$243,013
Previous $143,000
76.92%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AQST
# of Institutions
164Shares Held
65.9MCall Options Held
794KPut Options Held
457K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$52.9 Million100.0% of portfolio
-
Rtw Investments, LP New York, NY6.25MShares$33.7 Million0.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.66MShares$30.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$29.4 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.76MShares$20.3 Million0.05% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $288M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...